Skip to main content
Clinical Trials/CTRI/2019/10/021513
CTRI/2019/10/021513
Completed
Phase 4

Comparison of the efficacy of oxybutynin with that of mirabegron as an add-on therapy to tamsulosin in patients with persistent storage symptoms presumed to be due to benign prostatic hyperplasia : A randomized controlled trial

JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION RESEARCH0 sites96 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms
Sponsor
JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION RESEARCH
Enrollment
96
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
July 15, 2021
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION RESEARCH

Eligibility Criteria

Inclusion Criteria

  • Male patients aged 50 years or older with LUTS presumed to be due BPH having urinary urgency at least once per week and a total OAB symptom score (OABSS) ââ?°Â¥ 3 points after ââ?°Â¥ 8 weeks treatment with tamsulosin 0\.4mg od

Exclusion Criteria

  • 1\.PVR \> 100 ml
  • 2\.Q max \< 5 ml/s
  • 3\.Prior diagnosis of neurogenic bladder
  • 4\.Performance of clean intermittent catheterization,
  • 5\.Severe bladder diverticulum or urethral stricture,
  • 6\.Planning to have a child,
  • 7\.Suspected prostate or bladder malignancy
  • 8\.Previous urethral surgery or prior diagnosis of urethral stricture disease.
  • 9\.Previous intra pelvic irradiation,
  • 10\.Suspected recurrent urinary infection,

Outcomes

Primary Outcomes

Not specified

Similar Trials